Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Autor: S. Peters, J.-L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Mollá, R. Gervais, G. López Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J.L. González Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R.A. Stahel, C. Le Pechoux, D. De Ruysscher, R. Stahel, A. Hiltbrunner, M. Pardo-Contreras, A. Gasca-Ruchti, N. Giacomelli, R. Kammler, N. Marti, R. Pfister, A.C. Piguet, S. Roux, S. Troesch, M. Schneider, R. Schweri, I. Zigomo, Z. Tsourti, P. Zygoura, S. Tsouprou, M. Kassapian, G. Dimopoulou, C. Andriakopoulou, F. Morin, E. Amour, G. Mariaule, N. Archirel, M. Fernandez, E. Pereira, L. Benito, K. Lopez, A. Hernández, S. Chinchen, H. Jurkovic, A. Livingstone, J. Mitchell, M. Walker, S. Ng, C. Steer, K. Briscoe, A. Saqib, E. Abdi, B. Houghton, K. O’Byrne, B.R. Chittajallu, B.G. Hughes, A. Black, H. Werner, G. Zalcman, F. Vaylet, P. Merle, I. Monnet, N. Girard, P.-J. Souquet, F. Barlesi, D. Debieuvre, H. Senellart, M. Poudenx, A. Dixmier, D. Pouessel, J. Cadranel, H. Lena, E. Quoix, S. Friard, C. Audigier-Valette, E. Pichon, K. Kokowski, H. Kirchen, A. Tufman, C. De-Colle, J. de Langen, A. Insa, B. Massutí, M.P. Pulla, S.P. Aix, N. Villanueva, G.L. Vivanco, K. Franks, R. Califano

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
ETOP/IFCT 4-12 STIMULI Collaborators 2022, ' Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial ', Annals of Oncology, vol. 33, no. 1, pp. 67-79 . https://doi.org/10.1016/j.annonc.2021.09.011
Annals of Oncology, 33(1), 67-79. Oxford University Press

BACKGROUND: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25% to 33%. PATI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c0cd2636f83c5b87a3871c7a3d45ee
https://lirias.kuleuven.be/handle/123456789/682788

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

O Cyfra 21-1 é um determinante prognóstico no carcinoma pulmonar não de pequenas células (CPNPC): resultado de uma meta-análise que incluiu 2063 doentes

Autor: J.-L. Pujol, O. Molinier, W. Ebert, J.-P. Daurès, F. Barlési, G. Buccheri, M. Paesmans, E. Quoix, D. Moro-Sibilot, M. Szturmowicz, J.-M. Bréchot, T. Muley, J. Grenier

Publikováno v: Revista Portuguesa de Pneumologia, Vol 10, Iss 6, Pp 518-520 (2004)

RESUMO: O objectivo da presente meta-análise foi determinar o valor prognóstico de níveis séricos pré-terapêuticos elevados de Cyfra 21-1, ajustados a co-variáveis clássicas no CPNPC.Baseou-se em elementos registados em bases

Externí odkaz: https://doaj.org/article/1ad2c2dad0864ee9bdaa79ef6a0189ba

[Small cell lung cancer and immuno-oncologic agents: End of the cisplatin - etoposide era?]

Autor: J L, Pujol, B, Roch

Publikováno v: Revue des maladies respiratoires. 35(8)

In the setting of small cell lung cancer (SCLC), the development of immuno-oncological agents, particularly those targeting Programmed cell Death protein 1 (PD-1) and Programmed cell Death protein Ligand 1 (PD-L1), is still at an early stage. Two cri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4f095813c463ff6099c45c92f401704c
https://pubmed.ncbi.nlm.nih.gov/30174235

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.